artificial chromosomal (BAC) clones in triplicate and mapped these directly onto human genome sequence. The genetic alterations were classified the DNA copy-number variations according to the intensities of log2 ratio (Cy3/Cy5) as DNA copy-number loss/gain and deletion/amplification. Results: the whole genomic alterations in KKU-M213, which revealed a variety of chromosomal aberrations with a part and/or entire chromosomal gain and loss. Chromosomal amplifications were detected on 4q13. 1, 4q21.1, 4q21.2, 5p tel, and 5p15.3 , whereas homozygous deletions were detected on 1q23, 1q25, 1q31, 1q32-41, 1q32.2, 1q41, 1q43, 5q15-5q21, 8p22-8p23, 9p24, 10q11.2, 10q11.2-10q2.1, 10q11.2, 10q21.1 and 20q13.3 . Conclusions: The whole genome-wide genetic alterations were characterized which previously not defined in adenosquamous carcinoma. This recent advance tool is usefulness for discovering novel cancer-related gene (oncogene/tumor suppressor gene) and substitutes in in vivo experiment for functional testing of candidate gene involving liver fluke-associated ICC carcinogenesis. Acknowledgements: This work was supported by Faculty of Medicine, KKU, Thailand (Grant No. I51117 Background/Aims: We studied the clinical efficacy of arterial chemoinfusion therapy through an implanted port system for patients with intrahepatic cholangiocarcinoma (ICC). Thirty patients with unresectable ICC or intrahepatic recurrence of ICC after surgery were studied. Comparison was made between patients who received arterial chemoinfusion therapy through an implanted port system with adriacin and lecithin-added lipiodol emulsion in 5 patients and 5-fluorouracil (5-FU) in 7 patients. Eighteen patients were treated without port system. Results: Disease was stable in 5 patients with adriacin and lecithin-added lipiodol emulsion and in 3 patients with 5-FU. Disease was progressed in 4 patients with 5-FU. The mean survival period was 20.8 months in patients with adriacin and lecithin-added lipiodol emulsion, 9.3 months in patients with 5-FU, and 10.5 months in patients without port system (p=0.02, p=0.04). Conclusion: Arterial chemoinfusion therapy through an implanted port system is useful for patients with intrahepatic recurrence of ICC after surgery.